Combination of Talimogene Laherparepvec With Atezolizumab in Patients With Residual Breast Cancer After Standard Neoadjuvant Multi-agent Chemotherapy (PROMETEO TRIAL)
Latest Information Update: 10 Feb 2023
At a glance
- Drugs Atezolizumab (Primary) ; Talimogene laherparepvec (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms PROMETEO
Most Recent Events
- 27 Sep 2022 Planned End Date changed from 1 Nov 2023 to 27 Apr 2025.
- 01 Apr 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Jun 2022.
- 01 Apr 2022 Status changed from recruiting to active, no longer recruiting.